Literature DB >> 16695340

CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). III. STUDIES ON THE TOXICITY OF BAL ON PERCUTANEOUS AND PARENTERAL ADMINISTRATION.

M B Sulzberger1, R L Baer, A Kanof.   

Abstract

Entities:  

Year:  1946        PMID： 16695340      PMCID： PMC435586          DOI： 10.1172/JCI101730

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  4 in total

1.  BAL (BRITISH ANTI-LEWISITE).

Authors:  L L Waters; C Stock
Journal:  Science       Date:  1945-12-14       Impact factor: 47.728

2.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). VII. THE TREATMENT OF ARSENICAL DERMATITIS WITH PREPARATIONS OF BAL.

Authors:  W T Longcope; J A Luetscher; M M Wintrobe; V Jäger
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808

3.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). V. SKIN SENSITIZATION TO BAL.

Authors:  M B Sulzberger; R L Baer; A Kanof
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808

4.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). IV. PHARMACOLOGIC OBSERVATIONS ON BAL BY INTRAMUSCULAR INJECTION IN MAN.

Authors:  W Modell; H Gold; M Cattell
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808
  4 in total
  10 in total

1.  Gold dermatitis, treated with B.A.L.; toxic manifestations; related (?) to calcium deprivation.

Authors:  B GREEN; B F RUSSELL
Journal:  Proc R Soc Med       Date:  1948-02

2.  Bal in the Treatment of Gold Toxicity.

Authors:  J G Macleod
Journal:  Ann Rheum Dis       Date:  1948       Impact factor: 19.103

3.  British anti-lewisite; a report on its use and therapeutic value in arsenical intoxications, from the BAL Conference, Medical Research Council.

Authors:  R A PETERS; J BENNET
Journal:  Br Med J       Date:  1947-10-04

4.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). XI. THE TREATMENT OF ACUTE MERCURY POISONING BY BAL.

Authors:  W T Longcope; J A Luetscher; E Calkins; D Grob; S W Bush; H Eisenberg
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808

5.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). VII. THE TREATMENT OF ARSENICAL DERMATITIS WITH PREPARATIONS OF BAL.

Authors:  W T Longcope; J A Luetscher; M M Wintrobe; V Jäger
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808

6.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). V. SKIN SENSITIZATION TO BAL.

Authors:  M B Sulzberger; R L Baer; A Kanof
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808

7.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). II. THE EFFECT OF BAL ON THE EXCRETION OF ARSENIC IN NORMAL SUBJECTS AND AFTER MINIMAL EXPOSURE TO ARSENICAL SMOKE.

Authors:  J Wexler; H Eagle; H J Tatum; H J Magnuson; E B Watson
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808

8.  CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). IV. PHARMACOLOGIC OBSERVATIONS ON BAL BY INTRAMUSCULAR INJECTION IN MAN.

Authors:  W Modell; H Gold; M Cattell
Journal:  J Clin Invest       Date:  1946-07       Impact factor: 14.808

9.  Therapeutic potential of meso 2,3-dimercaptosuccinic acid or 2,3-dimercaptopropane 1-sulfonate in chronic arsenic intoxication in rats.

Authors:  S J Flora; S N Dube; U Arora; G M Kannan; M K Shukla; P R Malhotra
Journal:  Biometals       Date:  1995-04       Impact factor: 2.949

10.  N-Acetyl-Cysteine as Effective and Safe Chelating Agent in Metal-on-Metal Hip-Implanted Patients: Two Cases.

Authors:  Andrea Giampreti; Davide Lonati; Benedetta Ragghianti; Anna Ronchi; Valeria Margherita Petrolini; Sarah Vecchio; Carlo Alessandro Locatelli
Journal:  Case Rep Orthop       Date:  2016-04-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.